MarketCap
Facebook
X
TelegramQuartalsbericht 2022-Q1
hinzugefügt 27.06.2022
Dr. Reddy's Laboratories Limited Langfristige Verbindlichkeiten 2011-2026 | RDY
Langfristige Verbindlichkeiten Jährlich Dr. Reddy's Laboratories Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 9.04 B | - | - | - | 166 M | 221 M | 312 M | 423 M | 286 M | 365 M | 180 M |
Alle Zahlen in INR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 9.04 B | 166 M | 1.37 B |
Langfristige Verbindlichkeiten Vierteljährlich Dr. Reddy's Laboratories Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 8.28 B | - | - | - | 9.04 B | - | - | - | 4.44 B | - | - | - | 25.5 B | - | - | - | 29.5 B | - | - | - | 10.8 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in INR-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 29.5 B | 4.44 B | 14.6 B |
Langfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M |  USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
797 K | - | - | $ 8.42 M | USA |
 |
Aptorum Group Limited
APM
|
2.21 M | $ 0.88 | -1.73 % | $ 6.47 M | China |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
49.6 M | $ 22.48 | 0.81 % | $ 3.73 B | USA |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M |  Israel |
 |
Brainstorm Cell Therapeutics
BCLI
|
618 K | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
78.7 M | - | -4.8 % | $ 255 M | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cara Therapeutics
CARA
|
3.35 M | - | -3.03 % | $ 260 M | USA |
 |
CASI Pharmaceuticals
CASI
|
38.2 M | - | - | $ 35.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
5.46 M | - | -0.88 % | $ 598 M | USA |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
854 K | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
341 M | $ 101.39 | -0.66 % | $ 27.2 B | Germany |
 |
Checkpoint Therapeutics
CKPT
|
2.47 M | - | - | $ 169 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
90.3 M | $ 4.06 | -0.98 % | $ 434 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
167 M | $ 23.08 | -1.45 % | $ 2.94 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.49 | 4.58 % | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
30.8 B | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
276 K | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 2.92 | -0.14 % | $ 4.81 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
bluebird bio
BLUE
|
219 M | - | - | $ 546 M | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
ContraFect Corporation
CFRX
|
9.41 M | - | -5.16 % | $ 5.39 M | USA |
 |
Cardiff Oncology
CRDF
|
451 K | $ 1.7 | -1.45 % | $ 114 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
1.17 M | - | - | $ 1.2 B | USA |
 |
BioXcel Therapeutics
BTAI
|
1.4 M | $ 1.06 | -3.21 % | $ 12.9 M | USA |
 |
Cabaletta Bio
CABA
|
43.9 M | $ 2.83 | -2.92 % | $ 284 M | USA |